ASH News Daily - Monday, December 12, 2011 - (Page B-30)

Page B–30 ® ASH NewS DAily and administration while trying to maintain a fulfilling family life has made for an exciting but complex lifestyle,” he admits. “I am constantly on the run.” As part of this balancing act, Dr. Daley enjoys traveling with his family, playing sports with his kids, and cooking for his family and friends. In fact, had it not been for his interest in hematology, he might have acquiesced to his secret ambition of becoming a sommelier at a three-star Michelin-rated restaurant in southern France. “Bringing family and friends together around the table,” he says, “is one of the most treasured traditions in life.” In the professional realm, Dr. Daley’s greatest joy is witnessing his graduate students receive their degrees. To those who are considering joining in the journey of hematology, he gives this weighty nugget of wisdom: “Revel in the clinical and scientific richness of hematology, but continue to push the frontiers of knowledge to improve the health and vitality of our patients. There is still so much more to learn and so much more promise to deliver.” Plan to attend Dr. Daley’s lecture today from 9:00 to 10:00 a.m. in Hall AB. Monday, December 12, 2011 Thomas Lecture «« From Page B-1 mutations and evaluate drugs that can target them. On a larger scale, he hopes to focus on the root of the problem and reprogram adult tissue cells from an individual patient so they revert to an embryonic state; theoretically, this fundamental state will open the adult cells to be influenced to develop as healthy replacement tissues. Eagerly pursuing his passion, Dr. Daley remains challenged by the tasks vying for his attention. “Juggling the many busy aspects of science, patient care, teaching, “Revel in the clinical and scientific richness of hematology, but continue to push the frontiers of knowledge to improve the health and vitality of our patients. There is still so much more to learn and so much more promise to deliver.” Hodgkin lymphoma— ≈10% refractory rates1 ≈ 30% relapse rates after complete response1 ≈ 50% of transplants fail2,3 Long-term health complications4 Reduced survival in some patients initially cured5 NoGoodCancer.com Visit us at ASH booth 129 References 1. Quddus F, Armitage JO. Salvage therapy for Hodgkin’s lymphoma. Cancer J. 2009;15(2):161-163. 2. Sureda A, Constans M, Iriondo A, et al; The Grupo Español de Linfomas/Transplante Autólogo de Médula Osea (GEL/TAMO) Cooperative Group. Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin’s lymphoma autografted after a first relapse. Ann Oncol. 2005;16(4):625-633. 3. Majhail NS, Weisdorf DJ, Defor TE, et al. Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin’s lymphoma. Biol Blood Marrow Transplant. 2006;12(10):1065-1072. 4. Aleman BMP, van den Belt-Dusebout AW, Klokman WJ, Van’t Veer MB, Bartelink H, van Leeuwen FE. Long-term cause-specific mortality of patients treated for Hodgkin’s disease. J Clin Oncol. 2003;21(18):3431-3439. 5. Martinez C, Canals C, Alessandrino E, et al; Lymphoma Working Party of the EBMT. Relapse of Hodgkin’s lymphoma (HL) after autologous stem cell transplantation (ASCT): prognostic factors in 462 patients registered in the database of the EBMT. J Clin Oncol. 2010;28(15)(suppl):8060. Seattle Genetics and are US registered trademarks of Seattle Genetics, Inc. © 2011 Seattle Genetics, Inc., Bothell, WA 98021 All rights reserved US/BVP/2011/0138 003192_sgn35_ngc_and_fa1.indd 1 10/24/11 1:14 PM 

Table of Contents for the Digital Edition of ASH News Daily - Monday, December 12, 2011

ASH News Daily - Monday, December 12, 2011

https://www.nxtbookmedia.com